OLEMA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.95 USD | +1.22% |
|
+0.20% | -29.08% |
| Apr. 02 | Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target | MT |
| Mar. 18 | Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,840 | 372 | 98.27 | 766.3 | 556.5 | - | - |
| Enterprise Value (EV) 1 | 1,840 | 372 | 98.27 | 766.3 | 460.5 | 449.7 | 433.4 |
| P/E ratio | -14.1 x | -5.2 x | -0.94 x | -6.56 x | -4.11 x | -3.72 x | -3.73 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 72.8 x |
| EV / Revenue | - | - | - | - | - | - | 56.7 x |
| EV / EBITDA | -85.5 x | -5.22 x | -0.92 x | -7.33 x | -3.28 x | -2.45 x | -1.88 x |
| EV / FCF | -92.4 x | -7.12 x | -1.19 x | -9.15 x | -3.87 x | -3.45 x | -3.01 x |
| FCF Yield | -1.08% | -14% | -83.9% | -10.9% | -25.8% | -29% | -33.2% |
| Price to Book | - | - | 0.5 x | 3.04 x | 3.92 x | 2.41 x | - |
| Nbr of stocks (in thousands) | 38,274 | 39,745 | 40,110 | 54,622 | 55,934 | - | - |
| Reference price 2 | 48.08 | 9.360 | 2.450 | 14.03 | 9.950 | 9.950 | 9.950 |
| Announcement Date | 3/17/21 | 2/28/22 | 3/9/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 7.647 |
| EBITDA 1 | - | -21.52 | -71.33 | -106.6 | -104.6 | -140.4 | -183.8 | -230.4 |
| EBIT 1 | - | -21.53 | -71.49 | -107 | -105 | -138.5 | -170.1 | -189.1 |
| Operating Margin | - | - | - | - | - | - | - | -2,472.46% |
| Earnings before Tax (EBT) 1 | - | -22.12 | -71.1 | -104.8 | -96.66 | -133.8 | -163.4 | -176.6 |
| Net income 1 | -4.316 | -23.99 | -71.1 | -104.8 | -96.66 | -133.7 | -163.3 | -176.6 |
| Net margin | - | - | - | - | - | - | - | -2,309.59% |
| EPS 2 | -0.6000 | -3.420 | -1.800 | -2.620 | -2.140 | -2.421 | -2.675 | -2.665 |
| Free Cash Flow 1 | - | -19.92 | -52.26 | -82.43 | -83.73 | -119 | -130.3 | -144 |
| FCF margin | - | - | - | - | - | - | - | -1,883.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 10/30/20 | 3/17/21 | 2/28/22 | 3/9/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -17.71 | -21.68 | -23.17 | -33.21 | -23.13 | -27.12 | -29.5 | -21.5 | -23.25 | -30.33 | -31.94 | -33.21 | -35.52 | -39.87 |
| EBIT 1 | -17.76 | -21.76 | -23.25 | -33.29 | -23.22 | -27.22 | -29.6 | -21.6 | -23.34 | -30.42 | -31.34 | -33.48 | -36.02 | -38.75 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -17.71 | -21.64 | -23.03 | -32.86 | -22.72 | -26.18 | -28.29 | -20.1 | -21.5 | -26.77 | -29.88 | -32.05 | -34.65 | -37.74 |
| Net income 1 | -17.71 | -21.64 | -23.03 | -32.86 | -22.72 | -26.18 | -28.29 | -20.1 | -21.5 | -26.77 | -29.88 | -32.05 | -34.65 | -37.74 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4500 | -0.5400 | -0.5800 | -0.8200 | -0.5700 | -0.6500 | -0.7000 | -0.4900 | -0.4800 | -0.4900 | -0.5439 | -0.5834 | -0.6227 | -0.6793 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/28/22 | 5/9/22 | 8/9/22 | 11/8/22 | 3/9/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/11/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 96 | 107 | 123 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -19.9 | -52.3 | -82.4 | -83.7 | -119 | -130 | -144 |
| ROE (net income / shareholders' equity) | - | -14.6% | -22.8% | -43.5% | -42.8% | -70.9% | -88.5% | -64.9% |
| ROA (Net income/ Total Assets) | - | -14% | -22.3% | -41% | -39.2% | -64.2% | -74.1% | - |
| Assets 1 | - | 171.4 | 319.3 | 255.8 | 246.3 | 208.3 | 220.3 | - |
| Book Value Per Share 2 | - | - | - | 4.900 | 4.620 | 2.540 | 4.130 | - |
| Cash Flow per Share | - | - | - | -2.050 | - | - | - | - |
| Capex 1 | - | 0.06 | 1.58 | 0.36 | - | 6 | 1.5 | 3 |
| Capex / Sales | - | - | - | - | - | - | - | 39.23% |
| Announcement Date | 10/30/20 | 3/17/21 | 2/28/22 | 3/9/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.95
USD
Average target price
25
USD
Spread / Average Target
+151.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.08% | 556M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- OLMA Stock
- Financials Olema Pharmaceuticals, Inc.
